Bristol-Myers Squibb Co at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) - Fireside Chat Transcript
All right. Hello, and welcome. My name is Michael Schmidt. I'm a senior biotech analyst with Guggenheim Securities. I'm joined today by my colleague, Seamus Fernandez, our pharma analyst. And we're super excited to be hosting Bristol-Myers Squibb today at our Targeted Protein Degradation Conference.
With us today, we have Rupert Vessey. Rupert, I'm just going to -- welcome. Thanks for joining us. And I'm just going to let you introduce yourself, maybe just briefly mention your background and your current role at Bristol.
Thanks, Michael. It's great to be here. I'm Rupert Vessey. I'm President of Research and Early Development at Bristol-Myers Squibb. I'm a physician scientist by background, and I've been working in the industry for about 25 years in a whole range of different aspects of discovery, early development and translational medicine.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |